ALLK Allakos Inc.

+1.65  (+5%)
Previous Close 36
Open 36.04
Price To Book 8.82
Market Cap 1585556671
Shares 42,113,059
Volume 169,204
Short Ratio
Av. Daily Volume 375,052

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due 2Q 2019.
Severe Allergic Conjunctivitis
Phase 1 data released February 19, 2019.
Indolent Systemic Mastocytosis
Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
Chronic Urticaria
Phase 2 top-line data due mid-2019.
Eosinophilic Gastritis

Latest News

  1. Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights
  2. State-backed VC vehicle managers aren't worried about dipping into tax credits – here's why
  3. Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis
  4. Allakos Enters Oversold Territory
  5. Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
  6. Allakos to Host Investor Day on February 19 in New York City
  7. Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism
  8. Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients
  9. Here are the winners and losers from Bay Area's IPO class of 2018
  10. 5 Best-Performing IPOs of 2018
  11. Allakos (ALLK) Catches Eye: Stock Jumps 6.5%
  12. Here's how much better insiders have profited from this year's IPO boom
  13. Has Allakos Inc (NASDAQ:ALLK) Got Enough Cash?
  14. New Research Coverage Highlights TheStreet, EVO Payments, Odyssey Marine Exploration, Allakos, SORL Auto Parts, and SPAR Group — Consolidated Revenues, Company Growth, and Expectations for 2018
  15. Allakos Announces Clinical Update and Third Quarter 2018 Financial Results
  16. Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech